Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations.
Understanding resistance to antiretroviral therapy plays an ever more crucial role in managing HIV infection as new agents - including several in new antiretroviral classes - promise better control of multidrug-resistant virus in the developed world. Yet these new drugs have different, and often complex, resistance profiles. At the same time, resistance has assumed a key role in developing countries as access to additional antiretrovirals expands in the face of first-line regimen failures. Every year the International HIV Drug Resistance Workshop gathers leading investigators and resistance-savvy clinicians to share unpublished, peer-reviewed research on the mechanisms, pathogenesis, epidemiology, and clinical implications of resistance to licensed and experimental antivirals. The 2007 workshop, held on 12-16 June, proved particularly notable for its exploration of resistance to two new antiretroviral classes, integrase inhibitors and CCR5 antagonists, as well as to agents that control hepatitis C virus (HCV) infection. This report summarizes most oral presentations from the workshop and many posters.
Mascolini
Mark
M
VA San Diego Healthcare System, San Diego, USA.
Richman
Douglas
D
Larder
Brendan
B
Mellors
John
J
Boucher
Charles A B
CA
D019380:Anti-HIV Agents / Q000494:pharmacology*; D065100:CCR5 Receptor Antagonists; D017326:Clinical Trials, Phase III as Topic; D024882:Drug Resistance, Viral; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D019429:Integrase Inhibitors / Q000494:pharmacology*; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D019429:Integrase Inhibitors; D018894:Reverse Transcriptase Inhibitors